Figure 1

Schedule of research visits. * Subjects treated and followed for 48 weeks only (HCV monoinfected - G1/4; HIV/HCV coinfected - all genotypes). a) Full Baseline ACASI survey includes measures of: adherence [33]; opiate withdrawal [34]; recent drug and alcohol use [5, 35]; alcohol dependence [36]; HCV-related adherence knowledge [5, 37]; attitudes towards HCV medications [5, 37]; adherence self-efficacy [5, 37]; medication side effects [5]; coping [38]; depression (BDI-II and PHQ-9)[39–41]; psychological distress (hostility subscale)[42–44]; loneliness [45]; social support [46]; acculturation [47, 48]; patient-provider relationship [49]; cognitive function [50–52]; Barriers and Facilitators to Care [37]. b) Long ACASI survey includes measures of: adherence [33]; opiate withdrawal [34]; on-site social support; depression (BDI-II and PHQ-9)[39–41]; psychological distress (hostility subscale)[42–44]; recent drug and alcohol use [5, 35]; medication side effects [5]; HCV-related adherence knowledge (wks 8 and 16 only) [5, 37]; attitudes towards HCV medications (wks 8 and 16 only)[5, 37]; adherence self-efficacy (weeks 8 and 16 only) [5, 37]. c) Short ACASI survey includes measures of: adherence [33]; depression (BDI-II and PHQ-9)[39–41]; medication side effects [5]; opiate withdrawal [34]. d) Urine tested for methadone, opiates, cocaine, benzodiazepines, barbiturates, and amphetamines.